(CIRRUS-2023-1) CLINICAL CLIN Assessment of PathFinder 1.0 on the CIRRUS 6000 and the CIRRUS 5000

• PathFinder 1.0 on CIRRUS HD-OCT (Device): Participants undergo standard OCT imaging on CIRRUS HD-OCT systems, and the investigational PathFinder software analyzes the images for macular abnormalities without influencing clinical care.

Primary outcomes

• Sensitivity of PathFinder 1.0 [Baseline (single study visit OCT acquisition)]: Sensitivity is the proportion of scans that PathFinder 1.0 correctly identifies as having any macular abnormality.
• Specificity of PathFinder 1.0 [Baseline (single study visit OCT acquisition)]: Specificity is the proportion of scans that PathFinder 1.0 correctly identifies as having no macular abnormality.

Secondary outcomes

• Sensitivity and specificity by clinical diagnosis [Baseline]: Sensitivity and specificity of PathFinder 1.0, calculated separately within each PI-recorded diagnosis group.
• Sensitivity by macular abnormality type [Baseline]: Sensitivity of PathFinder 1.0 calculated separately for each OCT lesion type.
• Positive Predictive Value and Negative Predictive Value [Baseline]: Positive Predictive Value is the proportion of B-scans called abnormal by PathFinder 1.0.
• Rate of acceptable versus unacceptable B-scans [Baseline]: Proportion of B-scans within each macular cube, and overall, that is marked as "acceptable" or "unacceptable".
• Algorithm repeatability (precision) [Baseline]: Repeatability of PathFinder 1.0 results, expressed as the consistency of the proportion of abnormal B-scans per macular cube across repeated scans.

Sex: All, ages: 18 Years to any, accepts healthy volunteers

Inclusion Criteria:

1. Able and willing to make the required study visits.
2. Able and willing to give written informed consent and follow study instructions.
3. Able and willing to complete ophthalmic imaging.
4. Adults 18 years of age or older.

The subject population will be comprised of two groups (all categories below pertain to the central 6x6 mm macula area):

Group A

1\. Subjects with absence of macular abnormalities Group B

1. Subjects with Disruption of the vitreoretinal interface (VRI)
2. Subjects with Intraretinal hyporeflective space (IRHS)
3. Subjects with Subretinal hyporeflective space (SRHS)
4. Subjects with IS/OS (Ellipsoid Zone) disruption
5. Subjects with Retinal Pigment Epithelium (RPE) elevation
6. Subjects with Retinal Pigment Epithelium (RPE) atrophy
7. Other abnormalities

Exclusion Criteria:

1. Inability to undergo the required tests.
2. Unable to give consent or follow study instructions.
3. Inability to fixate that precludes obtaining acceptable macula scans in the study eye.
4. Visudyne (verteporfin) injection within the last 48 hours in the study eye.
5. Pilocarpine or Vuity use within the last 24 hours in the study eye.
6. Dense media opacity precluding adequate visualization of the retina in the study eye.
7. Vitreous floaters that preclude obtaining acceptable scans in the study eye.